This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of pregnant individuals who have OUD and their babies.
Dashboard: Filter Bricks
Main page content
![](/sites/default/files/styles/product_thumbnail_dashboard/public/pep23-02-01-002.jpg?itok=sV7Gt58k)
![Working with Child Protective Services to Support Pregnant and Parenting People, Their Infants, and Families Affected by Substance Use Disorders: A Factsheet for Health Care Providers](/sites/default/files/styles/product_thumbnail_dashboard/public/pep23-02-00-004.png?itok=U9Oi1kFn)
This document accompanies the Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. It offers information about child welfare systems and what the health care provider's role is in developing a Plan of Safe Care.
![Preparing For Your Baby: Information for Pregnant People with Substance Use Disorders](/sites/default/files/styles/product_thumbnail_dashboard/public/pep23-02-00-001.png?itok=Y2sL0v8i)
The fourth supplemental resource to SAMHSA’s Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. This document contains information for pregnant people with a substance use disorder and preparing to deliver.
![](/sites/default/files/styles/product_thumbnail_dashboard/public/pep21-02-01-003.png?itok=55xy8Ysh)
The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
![](/sites/default/files/styles/product_thumbnail_dashboard/public/pep21-02-01-002.png?itok=6OxqiQyG)
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
![Are You Taking Medicine for Opioid Use Disorder and Are Pregnant or Thinking about Having a Baby?](/sites/default/files/styles/product_thumbnail_dashboard/public/pages_from_pre-pregnancy-poster_508.jpg?itok=rxKFXhoo)
This poster is for clients and their family members in OUD treatment who are pregnant or who are currently not pregnant but of childbearing age.
![Pregnancy Planning for Women Treated for Opioid Use Disorder](/sites/default/files/styles/product_thumbnail_dashboard/public/pre_pregnancy_factsheet-508.jpg?itok=M4fvlIfk)
This fact sheet is for women who are pregnant or of childbearing age with an opioid use disorder
![The Facts about Buprenorphine for Treatment of Opioid Addiction (Cambodian/Khmer Version)](/sites/default/files/styles/product_thumbnail_dashboard/public/sma16-4442khmer.jpg?itok=qgOATVAS)
Gives patients information on buprenorphine and medication-assisted treatment for opioid addiction. Describes addiction and withdrawal, how buprenorphine works, its proper use, its side effects, and how it fits with counseling in the recovery process.
![The Facts About Buprenorphine for Treatment of Opioid Addiction (Spanish version)](/sites/default/files/styles/product_thumbnail_dashboard/public/sma15-4442spanish.jpg?itok=nNM13TEi)
Esta hoja de hechos ofrece informacion a los pacientes sobre la buprenorfina y los tratamientos con ayuda de medicamentos para tratar el trastorno por uso de opioides, y tambien describe el mal uso y los sintomas del sindrome de abstinencia. Explica como funciona la buprenorfina, su uso apropiado, sus efectos secundarios y como se la utiliza en conjunto con al consejeria en el proceso de recuperacion.